Check out the Fall 2021 Provider Newsletter Online! – This edition includes Fee Schedule Changes for 2022, Diagnosis Code Requirements for Dental Claims, Dental Bill of Rights and Supplementing Guidance for Treatment Planning and Radiographic Imaging Requirements and more.
As you know, the Connecticut State Dental Association (CSDA) has had some significant successes in recent years, including key victories earlier this year on central components of the Dental Bill of Rights.
The DSS is requiring that all dental providers who will perform more than one endodontic, crown or prosthodontic procedure on a HUSKY Health member’s permanent dentition submit a treatment plan document with radiographic imaging and supporting documentation to the Connecticut Dental Health Partnership (CTDHP) as described in Provider Bulletin PB 2021-61.
This virtual educational activity (webinar) on Tuesday, October 19, 2021 from 5:30 PM to 6:30 PM is jointly provider by Connecticut Hospital Association in collaboration with the Connecticut Department of Mental Health and Addiction Services.
Pregabalin (Lyrica) was originally FDA approved as an anti-epileptic drug, also called an anticonvulsant. It works by slowing down impulses in the brain that causes seizures. Pregabalin also affects chemicals in the brain that send pain signals across the nervous system and is used to control neuropathies, or nerve pain and “Restless Leg Syndrome”.
Effective for dates of service September 1, 2021 and forward, the Department of Social Services (DSS) is implementing dental claim submission diagnosis code requirements to further align electronic claim submission with the 2019 American Dental Association Form common format for reporting dental services.
Dental professionals should get vaccinated for COVID-19 and other infectious diseases, according to the Connecticut State Dental Association in a recently released statement. The Association, which advocates for its 2,300 members statewide, “strongly” encourages dental professionals to get vaccinated in accordance with the American Dental Association’s policy, the statement reads.
CDC has updated its COVID-19 guidance for Dental settings to avoid aerosol-generating procedures in a typical dental operatory only for patients with suspected or confirmed COVID-19. It has removed the language stating that dental health care personnel should avoid aerosol-generating procedures for all patients, regardless of their COVID-19 status.
Effective for dates of service August 1, 2021 and forward, the Department of Social Services (DSS) is updating the dental guidelines concerning radiographic coverage. The dental regulations and policies have been put in place to reduce dental procedures that are not medically necessary while maintaining services that will prevent further disease and continue the maintenance of oral health.
Exparel (bupivacaine liposome injectable suspension) is the first and only non-opioid, FDA-approved long-acting local anesthesia for ages 6 and above.